Literature DB >> 16320348

Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?

C H To1, M Petri.   

Abstract

OBJECTIVE: To examine autoantibody clusters and their associations with clinical features and organ damage accrual in patients with systemic lupus erythematosus (SLE).
METHODS: The study group comprised 1,357 consecutive patients with SLE who were recruited to participate in a prospective longitudinal cohort study. In the cohort, 92.6% of the patients were women, the mean +/- SD age of the patients was 41.3 +/- 12.7 years, 55.9% were Caucasian, 39.1% were African American, and 5% were Asian. Seven autoantibodies (anti-double-stranded DNA [anti-dsDNA], anti-Sm, anti-Ro, anti-La, anti-RNP, lupus anticoagulant (LAC), and anticardiolipin antibody [aCL]) were selected for cluster analysis using the K-means cluster analysis procedure.
RESULTS: Three distinct autoantibody clusters were identified: cluster 1 (anti-Sm and anti-RNP), cluster 2 (anti-dsDNA, anti-Ro, and anti-La), and cluster 3 (anti-dsDNA, LAC, and aCL). Patients in cluster 1 (n = 451), when compared with patients in clusters 2 (n = 470) and 3 (n = 436), had the lowest incidence of proteinuria (39.7%), anemia (52.8%), lymphopenia (33.9%), and thrombocytopenia (13.7%). The incidence of nephrotic syndrome and leukopenia was also lower in cluster 1 than in cluster 2. Cluster 2 had the highest female-to-male ratio (22:1) and the greatest proportion of Asian patients. Among the 3 clusters, cluster 2 had significantly more patients presenting with secondary Sjögren's syndrome (15.7%). Cluster 3, when compared with the other 2 clusters, consisted of more Caucasian and fewer African American patients and was characterized by the highest incidence of arterial thrombosis (17.4%), venous thrombosis (25.7%), and livedo reticularis (31.4%). By using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, the greatest frequency of nephrotic syndrome (8.9%) was observed in patients in cluster 2, whereas cluster 3 patients had the highest percentage of damage due to cerebrovascular accident (12.8%) and venous thrombosis (7.8%). Osteoporotic fracture (11.9%) was also more common in cluster 3 than in cluster 2.
CONCLUSION: Autoantibody clustering is a valuable tool to differentiate between various subsets of SLE, allowing prediction of subsequent clinical course and organ damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16320348     DOI: 10.1002/art.21414

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  41 in total

1.  Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study.

Authors:  María Del Carmen Zamora-Medina; Andrea Hinojosa-Azaola; Carlos A Nuñez-Alvarez; Angel Gabriel Vargas-Ruiz; Juanita Romero-Diaz
Journal:  Clin Rheumatol       Date:  2018-12-04       Impact factor: 2.980

Review 2.  The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease.

Authors:  Alina Dima; Ciprian Jurcut; Cristian Baicus
Journal:  Rheumatol Int       Date:  2018-05-23       Impact factor: 2.631

3.  Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes.

Authors:  Q-Z Li; J Zhou; A E Wandstrat; F Carr-Johnson; V Branch; D R Karp; C Mohan; E K Wakeland; N J Olsen
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

4.  Prognosis of patients with systemic lupus erythematosus and discoid lesions.

Authors:  Thelma Larocca Skare; Bárbara Stadler; Emilio Weingraber; Diogo F De Paula
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

5.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

6.  Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus.

Authors:  Joseph F Merola; Stephen D Prystowsky; Christina Iversen; Jose A Gomez-Puerta; Tabatha Norton; Peter Tsao; Elena Massarotti; Peter Schur; Bonnie Bermas; Karen H Costenbader
Journal:  J Am Acad Dermatol       Date:  2013-03-28       Impact factor: 11.527

7.  Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort.

Authors:  Mariangelí Arroyo-Ávila; Yesenia Santiago-Casas; Gerald McGwin; Ryan S Cantor; Michelle Petri; Rosalind Ramsey-Goldman; John D Reveille; Robert P Kimberly; Graciela S Alarcón; Luis M Vilá; Elizabeth E Brown
Journal:  Clin Rheumatol       Date:  2015-04-22       Impact factor: 2.980

8.  Systemic lupus erythematosus and Raynaud's phenomenon.

Authors:  Flavia Emilie Heimovski; Juliana A Simioni; Thelma Larocca Skare
Journal:  An Bras Dermatol       Date:  2015 Nov-Dec       Impact factor: 1.896

9.  Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.

Authors:  Lisa G Rider; Peter A Lachenbruch; Jason B Monroe; Angelo Ravelli; Imelda Cabalar; Brian M Feldman; Maria L Villalba; Barry L Myones; Lauren M Pachman; Robert M Rennebohm; Ann M Reed; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2009-11

10.  High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus.

Authors:  Shin-Seok Lee; Sukhminder Singh; Kimberly Link; Michelle Petri
Journal:  Semin Arthritis Rheum       Date:  2008-01-25       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.